Details of Disease

General Information of Disease (ID: DISGY3B0)

Disease Name	Intermittent claudication
Synonyms	Charcot's syndrome; intermittent claudication
Disease Class	BD40: Arterial occlusive disease
Definition	A symptom complex characterized by pain and weakness in skeletal muscle group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial stenosis; muscle ischemia; and accumulation of lactate.
Disease Hierarchy	DISK5QGC: Arteriosclerosis DISXSU1Y: Peripheral vascular disease DISGY3B0: Intermittent claudication
ICD Code	ICD-11 ICD-11: BD40.00 ICD-9 ICD-9: 440.21 Expand ICD-9 440.21
Disease Identifiers	MONDO ID MONDO_0005295 MESH ID D007383 UMLS CUI C0021775 MedGen ID 7115 HPO ID HP:0004417 SNOMED CT ID 63491006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cilostazol	DMZMSCT	Approved	Small molecular drug	[1]
Pentoxifylline	DMU3DNC	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LLG783	DMLBMU3	Phase 2	NA	[3]
ANGX-1039	DMERIKK	Phase 1	NA	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Palux	DMQM2JL	Discontinued in Phase 2	Small molecular drug	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PADI4	TTQHAXM	Limited	Biomarker	[6]
FURIN	TTH9WF6	moderate	Biomarker	[7]
BAK1	TTFM7V0	Strong	Biomarker	[8]
BBC3	TT7JUKC	Strong	Biomarker	[8]
EPAS1	TTWPA54	Strong	Therapeutic	[9]
MDM2	TT9TE0O	Strong	Therapeutic	[8]
SIRT2	TTLKF5M	Strong	Biomarker	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DTT(s)

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANGPTL6	OTOQ5W67	Limited	Altered Expression	[10]
DHX40	OTOL02QN	Limited	Biomarker	[6]
AGXT2	OTO6QUTM	Strong	Genetic Variation	[11]
BAD	OT63ERYM	Strong	Biomarker	[8]
EIF3E	OTI0WG98	Strong	Therapeutic	[9]
KLRB1	OTQ2959Y	Strong	Genetic Variation	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7148).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7095).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020971)
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034232)
6	Underutilization of Evidence-Based Smoking Cessation Support Strategies Despite High Smoking Addiction Burden in Peripheral Artery Disease Specialty Care: Insights from the International PORTRAIT Registry.J Am Heart Assoc. 2018 Oct 16;7(20):e010076. doi: 10.1161/JAHA.118.010076.
7	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).Circulation. 2017 Apr 11;135(15):1417-1428. doi: 10.1161/CIRCULATIONAHA.116.025707. Epub 2017 Feb 16.
8	Over-expression of PUMA correlates with the apoptosis of spinal cord cells in rat neuropathic intermittent claudication model.PLoS One. 2013 May 2;8(5):e56580. doi: 10.1371/journal.pone.0056580. Print 2013.
9	Silencing of int6 gene restores function of the ischaemic hindlimb in a rat model of peripheral arterial disease.Cardiovasc Res. 2011 Nov 1;92(2):209-17. doi: 10.1093/cvr/cvr203. Epub 2011 Jul 19.
10	Angiopoietin-related growth factor is independently associated with lower extremity peripheral arterial disease.J Diabetes Complications. 2017 Feb;31(2):433-438. doi: 10.1016/j.jdiacomp.2016.10.019. Epub 2016 Oct 27.
11	Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes.Diabetes Care. 2014;37(3):846-54. doi: 10.2337/dc13-0546. Epub 2013 Nov 1.
12	Relationship of the platelet glycoprotein PlA and fibrinogen T/G+1689 polymorphisms with peripheral arterial disease and ischaemic heart disease.Thromb Res. 2003;112(4):209-16. doi: 10.1016/j.thromres.2003.11.010.